Biopharmaceutical research and development is sure to dramatically increase the number of injectable drugs coming to market over the next few years. While advanced drug delivery techniques continue to hold promise for unique methods of administration, the traditional injection is still the dominant paradigm. However, the staggering costs and intransigent safety problems associated with sharps, along with consumer demand and the move to alternate-site care, are pushing for alternatives to traditional needles and syringes faster than advanced delivery technologies can come online.
The alternative in the short term appears to be the growing industry of needle-free injection and safety-engineered syringes. These devices, ranging from simple sheathed safety needles to complex gas jet injection systems, are competing in a vigorous marketplace, some sectors of which are growing at an annual rate in excess of 20%.
This report analyzes the current world market for needle-free drug delivery injection systems and safety syringes in terms of dollar volume and unit sales and makes forecasts through 2009. Regional geographic segmentations are also provided through the forecast period in both units and dollars. The report discusses the market’s drivers and constraints and provided pertinent data on the epidemiology of needlestick injuries, the value of injectable drug markets, and other related issues and trends. It also profiles more than 25 companies involved in marketing or developing these devices, including Antares Pharma, Becton Dickinson, Bioject, D’Antonio Consultants International, Retractable Technologies, Safety Syringes Inc., and Tyco Healthcare.
Market forecasts are based on an examination of current market conditions and on investigations into the development of new products by key companies. The information presented in this report is the result of data gathered from company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press. In addition, interviews were conducted with company executives, clinicians, researchers and public health officials.